Member Info for RayPointer

It will be interesting if a clear winner comes out of this in terms of the approach used

mNRA
adenovirus
DNA

Plus any other approach of which there are many.

I can't help thinking the it will be a competition between the 2 new kids on the block mNRA and DNA.
Of course, Lindy's vaccine will be way out in front :-)

LOL

Ruck
"I think the point they are making is that the cost of getting a drug to market is greater than the cash in the bank"
Getting a drug to market will be via deals. This is a point that has been so often discussed. Get the P1/P2 data and then get the deals.
ATB

Thanks WTP

"Drugs R&D is expensive business, and Scancell may well be forced to tap shareholders for cash before too long."

The above sentence appears to be a little under-researched.
The cash in hand will not last for ever, but it is by far the best cash position ever for Scancell.
I suspect this a standard sentence the Fool uses for a small biotech company and, in this case, they didn't bother checking.

The first half pint is on me ;-)

Nightclubs are open again AB if you fancy getting out of the house :-)

One from team ramp and one from team doom.
Try to keep up with the politics AB :-)

As Lindy said in the Oxford presentation, the SCIB1 is now showing 4 locations recruiting.

https://clinicaltrials.gov/ct2/show/NCT04079166#contacts

I just wonder if the plans still include the US with Keith Flaherty being the clinician. It would be great if that were so.

I found this quote on the Calculus website from 2nd May 2020, soon after starting the work on Covidity.

https://www.calculuscapital.com/coronavirus-vaccine-scientists-to-try-dna-treatment/

“Most vaccines stimulate strong neutralising antibodies but weak T-cell responses. Although this is good enough for many viruses, for coronaviruses it seems that strong T-cell responses are also required,”
Professor Durrant, Scancell"

It's so typical of Lindy that she appeared to be ahead of the curve at this early date.

20p is Diggle Wiggle territory :-)

The point is that it is likely that talks with 1 or more parties are taking place, but exact criteria to be met before a deal is possible for each of these parties is unknown.

If the safety, antibody and T Cell measures are good, then a deal may be on the cards before the P1 trial concludes.

Worst case scenario is that 1 party is involved and we have to wait until P1 concludes and it turns out that they walk away from a deal
Best case scenario we have more than 1 party involved and all parties are seriously interested in Covidity, and at the first sign of good antibody and TCell responses a deal appears.

It strikes me that there are no hard and fast rules to this.

The situation is not as urgent as it was for the 1st wave of vaccines. Having said that, if Covidity achieves its objectives, as outlined by Lindy in that Sky interview, then it becomes a much after commodity.
To be certain of its efficacy, a P3 trial needs to be carried out, but concluding a deal would be a huge step forward.

Securing a partner is crucial to the timeline. We have no way of knowing but hopefully Scancell are already in talks with one or more potential partners. Initial readings of safety and also antibody and T Cell levels may be enough for a partner to commit.

Anyway we now know why Elvis has not released a single for ages :-)

I have the impression that APCs do not have a problem when it comes to ingesting what it thinks is an infection.

https://courses.lumenlearning.com/wm-biology2/chapter/antigen-presenting-cells/

" An antigen-presenting cell (APC) is an immune cell that detects, engulfs, and informs the adaptive immune response about an infection. When a pathogen is detected, these APCs will phagocytose the pathogen and digest it to form many different fragments of the antigen. Antigen fragments will then be transported to the surface of the APC, where they will serve as an indicator to other immune cells."

So, the problem probably doesn't exist with moditope.
With immunobody, the vaccine has to enter both APCs and the soft muscle cells and the latter looks like it could be the problem.

https://www.scancell.co.uk/moditope

I'm not sure how difficult it is for the moditope peptides to gain entry into an APC.

https://www.isa-pharma.com/technology/amplivant-technology/

"ISA’s AMPLIVANT® technology comprises a proprietary and synthetic Toll-Like Receptor (TLR)1/2 ligand with enhanced immunostimulatory activity that can be coupled to the peptide in the standard SLP® manufacturing process. Long peptide-AMPLIVANT® conjugate immunotherapeutics allow lower dosing at higher efficacy through better dendritic cell antigen processing and presentation as well as enhanced T cell priming."

This tends to suggest that amplivant may help the moditope peptides to gain entry.

Thanks Bermuda
That's clarified things nicely.
It's all looking good for a trial start soon.

Morning crumbs
I also wondered whether the peptide delivery is now excluded.
Perhaps they are using both,.
The pharmajet devices seem to be more effective than needle delivery but how do they compare to electoporation?
That is the comparison that is relevant to Immunobody vaccines.

We had this from Ivy yesterday

"Needle-free injectors are known to augment DNA vaccine response, possibly by increased dispersion of injectate or through tissue disruption that increases immunogenicity. "

So, is that tissue disruption on the same scale as that produced by the electoporation electric field?
Remember the vaccine has to gain entry into not only APCs but also soft muscle cells in order to provide the dual presentation that is necessary to provide the augmented Immunobody response.

Is the normal head in for repairs?

The SCIB1 trial is already underway so I assume they cannot change the delivery method mid-trial.

A very worthy post Bermuda :-)